Analysis of a series pheochromocytoma cases over 15 years
Keywords:
feocromocitoma, catecolaminas, metanefrinas, médula adrenalAbstract
Background. The pheochromocytoma is a catecholamine secreting tumour derived from chromaffin cells of the sympathetic nervous system. Eighty to eighty-five percent of these tumours are localized in the adrenal medulla. When pheocromocytomas are found outside the adrenal gland they are referred to as extra-adrenal pheochromocytomas or paragangliomas. The diagnosis is confirmed by elevation of catecholamines and the metanephrines in blood plasma and urine. Localization of the tumour should be done following biochemical diagnosis by means of CT scan and/or MRI. The treatment of choice is tumour resection by laparoscopic surgery. Material and methods. A review was made of all patient medical histories diagnosed with pheochromocytoma confirmed by the pathology reports of Pathological anatomy of the Navarre hospital Complex (Anatomía patológica del Complejo hospitalario de Navarra A y B) between 1996 to 2010. Descriptive analysis was made using the IBM SPSS statistics program. Results. Our series consists of 43 patients diagnosed with pheochromocytoma over a span of 15 years. The average age on presentation was 47 years. Among the younger patients specific genetic syndromes were found. Computerized tomography was the most widely used method of localization. Contradictory results were found regarding perioperative medical management protocols. All pheocromocytoma tumours in this series were benign. Conclusions. It is advisable to carry out a genetic study on patients under twenty. The biochemical indicators with the greatest diagnostic sensitivity were the levels of normetanephrine and metanephrine in urine. Surgery was the only treatment option.Downloads
References
1. ILIAS I, PACAK K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 2008; 35 (Suppl. 1): S27-S34.
https://doi.org/10.1016/j.nucmedbio.2008.04.007
2. PACAK K, ILIAS I, ADAMS KT, EISENHOFER G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. Intern Med 2005: 257: 60-68.
https://doi.org/10.1111/j.1365-2796.2004.01425.x
3. WEISE M, MERKE D, PACAK K, WALTHER M, EISENHOFER G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 2002: 87: 1955-1960.
https://doi.org/10.1210/jcem.87.5.8446
4. ILIAS I, PACAK K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004: 89: 479-491.
https://doi.org/10.1210/jc.2003-031091
5. MANSMANN G, LAU J, BALK E, ROTHBERG M, MIYACHI Y, BORNSTEIN S. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004: 25: 309-340.
https://doi.org/10.1210/er.2002-0031
6. JACOBSON A, DENG H, LOMBARD J, LESSIG H, BLACK R. 123I-Meta-Iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010; 95: 2596-2606.
https://doi.org/10.1210/jc.2009-2604
7. HENRI JL, CHEN C, CARRASQUILLO J, WHATLEY M, LING A, HAVEKES B et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro- deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009: 94: 4757-4767.
https://doi.org/10.1210/jc.2009-1248
8. CASCO A, PITA G, BURNICHON N, LANDA I, JIMÉNEZ E, MONTERO-CONDE C et al. Genetics of pheochromocytoma and paraganglioma in spanish patients. J Clin Endocrinol Metab 2009: 94: 1701-1705.
https://doi.org/10.1210/jc.2008-2756
9. JIMÉNEZ C, COTE G, ARNOLD A, GAGEL R. Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006: 91: 2851-2858.
https://doi.org/10.1210/jc.2005-2178
10. BRAVO EL, TAGLE R. Pheochromocytomas: state of the art and future prospects. Endocr Rev 2003: 24: 539-553.
https://doi.org/10.1210/er.2002-0013
11. KINNEY MA, WARNER ME, VAN HEERDEN JA, HORLOCKER TT, YOUNG WF JR, SCHROEDER DR et al. Perianesthesic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg 2000: 91: 1118-1123.
https://doi.org/10.1213/00000539-200011000-00013
12. AMAR L, SERVAIS A, GIMENEZ-ROQUEPLO AP, ZINZINDOHOUE F, CHATELLIER G, PLOUIN PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005: 90: 2110-2116.
https://doi.org/10.1210/jc.2004-1398
13. LENDERS JW, PACAK K, WALTER MM, LINEHAN WM, MANNELLI M, FRIBERG P et al. Biochemical diagnosis of pheochromocytoma. Which test es best? JAMA 2002: 287: 1427-1434.
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
